Bikman B. Why We Get Sick.Dallas: Ben Bella Books, Inc; 2020

EMC. Package leaflet: Information for the patient wegovy FlexTouch. Hqrdtemplatecleanen v10.1. (accessed 12 March 2023)

FDA. OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval. 2017. (accessed 12 March 2023)

FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. 4 June 2021. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.: FDA;

Hall KD, Ayuketah A, Brychta R Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019; 30:67-77

Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. 2019; 10

Recommended weight-loss drug to be made available in specialist NHS services.: News | News | NICE; 2023a

The National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. 2023b. (accessed 12 March 2023)

Unwin J, Delon C, Glaever H Low carbohydrate and psychoeducational programs show promise for the treatment of ultra-processed food addiction. Front Psychiatry. 2022; 13

Unwin D, Delon C, Unwin J What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss. BMJ Nutr Prev Health. 2023; 0

Wilding JPH, Batterham RL, Calanna S Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384:989-1002

The risks and rewards of semaglutide in obesity treatment

02 April 2023
Volume 5 · Issue 4


George Winter discusses the potential of semaglutide, a hormone-mimicking drug, for weight loss in overweight and obese non-diabetic adults. While effective, the drug has adverse side effects and highlights the importance of lifestyle interventions in addressing overweight and obesity

The connection between the pancreas, the gut and incretins – hormones released into the blood by the intestine in response to food – was established in the early twentieth century (Knudsen and Lau, 2019). With the incretin hormone glucagon-like peptide-1 (GLP-1) shown to account for up to 70% of insulin secretion in response to nutrient intake, its therapeutic potential in type 2 diabetes (T2D) was realised, leading to the development of semaglutide, which mimics GLP-1 by promoting insulin release and reducing the blood concentration of glucose (Knudsen and Lau, 2019).

Although semaglutide has been used in the treatment of T2D, Wilding et al (2021) reported the results of a double-blind trial of 1961 non-diabetic adults with a body-mass index (BMI) of 30 or greater, randomly assigned ‘to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention’. They found that obese or overweight non-diabetic adults ‘had a mean weight loss of 14.9% from baseline with semaglutide as an adjunct to lifestyle intervention. This loss exceeded that with placebo plus lifestyle intervention by 12.4 percentage points’ (Wilding et al, 2021).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month